Questions?1-833-393-4363
*In 2 clinical trials, 642 and 640 people were treated monthly with VABYSMO or aflibercept 2 mg, respectively. On average, people with CRVO gained 13 letters on an eye chart at 1 month and people with BRVO gained 11 letters on an eye chart at 1 month for both treatments. On average, people with CRVO and BRVO gained 17 letters on an eye chart over 6 months for both treatments.
†In 2 clinical trials, VABYSMO was shown to help reduce excess damaging fluid in the eye, similar to aflibercept 2 mg.
‡VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.
Ang-2=angiopoietin-2; BRVO=branch retinal vein occlusion; CRVO=central retinal vein occlusion; VEGF=vascular endothelial growth factor.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.